← 產業報告目錄

Peripheral Vascular Devices Market by Type (Angioplasty Balloon & Angioplasty Stent, Catheters (IVUS/OCT), Plaque Modification, Vascular Closure Devices, Balloon Inflation Devices, Hemodynamic Flow Alteration), End User - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-02-16頁數 453報告編號 MD1254

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The peripheral vascular devices market is projected to reach USD 13.22 billion by 2031 from USD 10.02 billion in 2026, at a CAGR of 5.7% from 2026 to 2031. The peripheral vascular devices market is experiencing significant growth, driven by the rising prevalence of peripheral artery disease (PAD) and other vascular disorders. These conditions are largely linked to the aging population, along with rising rates of diabetes, obesity, and smoking. Innovations in minimally invasive endovascular devices, such as drug-coated balloons, next-generation stents, atherectomy systems, and embolic protection devices, are greatly improving clinical outcomes and expanding the range of patients who can be treated. Additionally, the growing preference for outpatient and ambulatory surgical center-based procedures, supported by favorable reimbursement policies in many regions, is accelerating the adoption of these devices. Furthermore, increasing awareness of early diagnosis and treatment, improvements in healthcare infrastructure in developing countries, and ongoing investments by major manufacturers in innovation and clinical research are all contributing to market growth. “The old/normal balloons segment is expected to grow at the highest CAGR in the angioplasty balloons market during the forecast period.” The angioplasty balloons market is experiencing increased demand for plain (standard) balloons due to their cost-effectiveness, availability of clinical expertise, and versatility across peripheral and coronary interventions. These balloons remain popular for lesion preparation, as well as for pre- and post-dilatation procedures, particularly when drug-coated options are either unnecessary or not covered by insurance. Despite the emergence of advanced balloon technologies, standard balloons continue to see strong sales in less demanding, high-volume markets, especially in developing countries, due to their ease of use, reliability, and compatibility with different stent systems. “The embolic protection devices segment is expected to grow at the highest CAGR in the hemodynamic flow alteration devices market during the forecast period.” Embolic protection devices are expected to see increased demand in the hemodynamic flow alteration devices market. This is due to their growing use in complex endovascular and structural heart procedures, where the risk of distal embolization is notably high. The rising awareness of procedure-related complications, such as stroke and organ ischemia—especially during carotid, peripheral, and transcatheter interventions—has accelerated their clinical adoption. Additionally, improvements in device design, which enhance capture efficiency, deliverability, and vessel compatibility, have significantly supported market growth. This trend is further bolstered by the introduction of established guidelines and the expansion of minimally invasive vascular procedures. “Based on end users, the ambulatory surgical centers segment is expected to grow at the highest CAGR in the peripheral vascular devices market during the forecast period.” The peripheral vascular devices market is experiencing significant growth, largely driven by the positive impact of ambulatory surgery centers (ASCs). These centers facilitate the shift toward minimally invasive procedures that prioritize the comfort and safety of outpatient care. ASCs offer numerous benefits, including lower procedural costs, faster patient turnover, shorter hospital stays, and improved operational efficiency, making them appealing to payers, providers, and patients alike. Innovations in peripheral vascular devices, such as miniaturized imaging systems, low-profile catheters, balloons, and atherectomy devices, have enabled even the most complex procedures to be performed in ASC settings. Additionally, favorable reimbursement policies, physician ownership models, increasing patient preference for same-day discharge, and the rising incidence of peripheral artery disease (PAD) are all contributing to the accelerated adoption of ASCs in this market. “The Asia Pacific is estimated to register the highest CAGR during the forecast period.” The primary driver of the peripheral vascular devices market in the APAC region is the rapidly increasing incidence of peripheral artery disease (PAD) and diabetes. This trend is supported by a large aging population and a global shift towards healthier lifestyles. Countries like China, India, and Japan are leading the way in adopting these devices, driven by developing healthcare infrastructure, rising healthcare expenditures, and improved access to advanced endovascular procedures. Additionally, growing awareness of the benefits of minimally invasive interventions, an increasing number of skilled interventional specialists, and a gradual but steady expansion of reimbursement coverage in key markets are also contributing to market growth. Furthermore, low-cost manufacturing, the presence of local companies, and the strategic expansion of global medical device firms are significant drivers of this market's growth in the APAC region. Key Players Some of the major players in this market are Boston Scientific (US), Medtronic Plc (US), Abbott (US), Becton, Dickinson and Company (US), Terumo Corporation (Japan), B. Braun Melsungen AG (Germany), Merit Medical Systems (US), Penumbra, Inc. (US), Koninklijke Philips (Netherlands), Stryker (US), Cordis (US), W.L. Gore & Associates (US), Biotronik Stryker (US), Endologix LLC (US), and Cook Medical (US), among others. Research Coverage The report analyzes the peripheral vascular devices market, estimating market size and future growth potential across various segments. These segments include angioplasty stents, endovascular aneurysm repair stent grafts, inferior vena cava filters, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. Additionally, the report includes a product portfolio matrix of various peripheral vascular devices available in the market. It also provides a competitive analysis of the key players in this market, detailing their company profiles, product offerings, and key market strategies. Reasons to Buy the Report This report will provide market leaders and new entrants with valuable revenue estimates for the overall peripheral vascular devices market and its subsegments. It will help stakeholders understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report will offer insights into the current market dynamics, highlighting key drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers: • Analysis of key drivers (rapid growth in geriatric population and resulting increase in disease prevalence and favorable reimbursement scenario for peripheral vascular procedures), restraints (availability of alternative treatment options and shortage of skilled professionals with expertise in peripheral vascular devices), opportunities (high growth potential in emerging markets and growing incidence of obesity & diabetes), and challenges (product failures and device recalls). • Product Developments/Enhancements: Comprehensive details about new product launches and anticipated trends in the global peripheral vascular devices market. • Product Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global peripheral vascular devices market. • Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. • Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the global peripheral vascular devices market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global peripheral vascular devices market.
目錄 Table of Contents
1 INTRODUCTION 37 1.1 STUDY OBJECTIVES 37 1.2 MARKET DEFINITION 37 1.3 MARKET SCOPE 38 1.3.1 MARKET SEGMENTATION 38 1.3.2 INCLUSIONS & EXCLUSIONS 39 1.3.3 YEARS CONSIDERED 39 1.3.4 CURRENCY CONSIDERED 39 1.4 MARKET STAKEHOLDERS 40 1.5 SUMMARY OF CHANGES 41 2 EXECUTIVE SUMMARY 42 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 42 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 43 2.3 DISRUPTIVE TRENDS IN PERIPHERAL VASCULAR DEVICES MARKET 44 2.4 HIGH GROWTH SEGMENTS 45 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 46 3 PREMIUM INSIGHTS 47 3.1 PERIPHERAL VASCULAR DEVICES MARKET OVERVIEW 47 3.2 ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE AND COUNTRY 48 3.3 PERIPHERAL VASCULAR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49 3.4 PERIPHERAL VASCULAR DEVICES MARKET: DEVELOPED VS. EMERGING ECONOMIES 49 4 MARKET OVERVIEW 50 4.1 INTRODUCTION 50 4.2 MARKET DYNAMICS 50 4.2.1 DRIVERS 51 4.2.1.1 Rapid growth in geriatric population 51 4.2.1.2 Favorable reimbursement scenario for procedures 51 4.2.1.3 Increasing number of product approvals 52 4.2.1.4 Rising prevalence of diabetes 53 4.2.1.5 Growth in tobacco consumption 53 4.2.1.6 Rising obesity rates 54 4.2.2 RESTRAINTS 55 4.2.2.1 Increasing number of product failures and recalls 55 4.2.2.2 Regulatory complexity and approval delays 56   4.2.3 OPPORTUNITIES 57 4.2.3.1 High growth potential in emerging markets 57 4.2.3.2 Increasing awareness and early diagnosis of PAD 57 4.2.4 CHALLENGES 58 4.2.4.1 Limited availability of alternative treatments 58 4.2.4.2 Dearth of skilled professionals with expertise in peripheral vascular devices 58 4.3 UNMET NEEDS AND WHITE SPACES 59 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 60 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 61 5 INDUSTRY TRENDS 62 5.1 PORTER’S FIVE FORCES ANALYSIS 62 5.1.1 THREAT OF NEW ENTRANTS 63 5.1.2 THREAT OF SUBSTITUTES 64 5.1.3 BARGAINING POWER OF SUPPLIERS 65 5.1.4 BARGAINING POWER OF BUYERS 65 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 66 5.2 MACROECONOMICS INDICATORS 66 5.2.1 INTRODUCTION 66 5.2.2 GDP TRENDS AND FORECAST 66 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 67 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 67 5.3 SUPPLY CHAIN ANALYSIS 68 5.4 VALUE CHAIN ANALYSIS 69 5.5 ECOSYSTEM ANALYSIS 70 5.6 PRICING ANALYSIS 71 5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025 71 5.6.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 72 5.7 TRADE ANALYSIS 73 5.7.1 IMPORT DATA FOR HS CODE 901839 73 5.7.2 EXPORT DATA FOR HS CODE 901839 75 5.8 KEY CONFERENCES AND EVENTS, 2026–2027 77 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 78 5.10 INVESTMENT AND FUNDING SCENARIO 78 5.11 CASE STUDY ANALYSIS 79 5.11.1 MEDTRONIC 79 5.11.2 TERUMO 80 5.11.3 BOSTON SCIENTIFIC CORPORATION 80   5.12 IMPACT OF 2025 US TARIFFS - PERIPHERAL VASCULAR DEVICES MARKET 81 5.12.1 INTRODUCTION 81 5.12.2 KEY TARIFF RATES 81 5.12.3 PRICE IMPACT ANALYSIS 82 5.12.4 IMPACT ON COUNTRIES/REGIONS 83 5.12.4.1 US 83 5.12.4.2 Europe 83 5.12.4.3 Asia Pacific 83 5.12.5 IMPACT ON END-USE INDUSTRIES 84 5.12.5.1 Hospitals 84 5.12.5.1.1 Large chain hospitals 84 5.12.5.1.2 Standalone hospital facilities 84 5.12.5.2 Ambulatory care settings 84 5.12.5.3 Cardiac care centers 85 5.12.5.4 Other end users 85 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86 6.1 TECHNOLOGY ANALYSIS 86 6.1.1 KEY EMERGING TECHNOLOGIES 86 6.1.1.1 Drug-eluting stents 86 6.1.1.2 Atherectomy devices 86 6.1.2 COMPLEMENTARY TECHNOLOGIES 87 6.1.2.1 Intravascular ultrasound 87 6.1.2.2 Optical coherence tomography 88 6.1.3 ADJACENT TECHNOLOGIES 88 6.1.3.1 Remote patient monitoring 88 6.1.3.2 3D printing and patient-specific modeling 89 6.2 TECHNOLOGY/PRODUCT ROADMAP 89 6.3 PATENT ANALYSIS 90 6.3.1 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR PERIPHERAL VASCULAR DEVICES MARKET, JANUARY 2015–DECEMBER 2025 90 6.3.2 LIST OF MAJOR PATENTS, 2023–2026 92 6.4 FUTURE APPLICATIONS 94 6.4.1 INTRAVASCULAR LITHOTRIPSY FOR CALCIFIED PAD LESIONS 94 6.4.2 ADVANCED IMAGE-GUIDED INTERVENTIONS 94 6.4.3 SMART SENSOR-INTEGRATED VASCULAR IMPLANTS 94 6.4.4 INTEGRATED MULTI-FUNCTION ENDOVASCULAR DEVICES 94 6.5 IMPACT OF AI ON PERIPHERAL VASCULAR DEVICES MARKET 95   7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 96 7.1 REGULATIONS AND COMPLIANCE 96 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 7.1.2 INDUSTRY STANDARDS 99 7.1.2.1 Medical Device Quality Management Standard (ISO 13485) 99 7.1.2.2 Biological Evaluation and Biocompatibility of Medical Devices (ISO 10993) 99 7.1.2.3 Vascular Stent Performance Standard (ISO 25539-2) 99 7.1.2.4 Intravascular Access Device Standard (ISO 11070) 100 7.2 SUSTAINABILITY INITIATIVES 100 7.2.1 SUSTAINABLE PACKAGING AND DIGITAL INSTRUCTIONS (BOSTON SCIENTIFIC CASE STUDY) 100 7.2.2 SUSTAINABLE PRODUCT LIFECYCLE MANAGEMENT (ABBOTT CASE STUDY) 100 7.2.3 PACKAGING WASTE REDUCTION INITIATIVE BY MEDTRONIC 101 7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS 101 8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 102 8.1 DECISION-MAKING PROCESS 102 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 103 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 103 8.2.2 BUYING CRITERIA 104 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 105 8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS 106 8.5 MARKET PROFITABILITY 106 8.5.1 SHIFT TOWARD HIGH-VALUE, DRUG-ELUTING, AND SPECIALTY DEVICES 106 8.5.2 PROCEDURE VOLUME GROWTH DRIVEN BY AGING POPULATION AND PAD PREVALENCE 106 8.5.3 COST OPTIMIZATION THROUGH SUPPLY CHAIN EFFICIENCY AND PORTFOLIO BREADTH 107 9 PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 108 9.1 INTRODUCTION 109 9.2 ANGIOPLASTY STENTS MARKET, BY TYPE 110 9.2.1 VOLUME ANALYSIS: ANGIOPLASTY STENTS MARKET, BY TYPE 110 9.2.2 DRUG-ELUTING STENTS 112 9.2.2.1 Drug-eluting stents to witness higher adoption due to technological advancements leading to lower restenosis rate 112 9.2.3 BARE-METAL STENTS 114 9.2.3.1 Bare-metal stents, by delivery platform 116 9.2.3.1.1 Balloon-expandable stents 116 9.2.3.1.1.1 Better radial strength and ease of deployment to drive usage 116   9.2.3.1.2 Self-expandable stents 118 9.2.3.1.2.1 Flexibility, tolerance, and support for vessel movement and compression to propel market 118 9.3 ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY TYPE 120 9.3.1 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS 122 9.3.1.1 Rising prevalence of AAA and need for less invasive treatment to drive market 122 9.3.2 THORACIC AORTIC ANEURYSM STENT GRAFTS 124 9.3.2.1 Increasing incidence of thoracic aortic aneurysms to propel adoption 124 9.4 CATHETERS MARKET, BY TYPE 126 9.4.1 ANGIOGRAPHY CATHETERS 128 9.4.1.1 Angiography catheters to dominate catheters market 128 9.4.2 GUIDING CATHETERS 130 9.4.2.1 Growing number of target procedures to drive demand for guiding catheters 130 9.4.3 IVUS/OCT CATHETERS 132 9.4.3.1 IVUS/OCT catheters segment to register highest growth 132 9.5 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE 134 9.5.1 RETRIEVABLE FILTERS 136 9.5.1.1 Retrievable filters segment to register higher growth due to increase in use as temporary measure to block pulmonary embolism 136 9.5.2 PERMANENT FILTERS 138 9.5.2.1 Advances in other technologies and risks associated with permanent filters to hamper sales 138 9.6 ANGIOPLASTY BALLOONS MARKET, BY TYPE 140 9.6.1 OLD/NORMAL BALLOONS 142 9.6.1.1 Old/normal balloons to dominate angioplasty balloons market as they remain effective and widely used 142 9.6.2 DRUG-ELUTING BALLOONS 144 9.6.2.1 Drug-eluting balloons to witness highest growth with increasing demand for angioplasty procedures and rising regulatory approvals for DEBs 144 9.6.3 CUTTING & SCORING BALLOONS 146 9.6.3.1 Preference for medication as primary treatment for atherosclerosis to restrain adoption 146 9.7 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 148 9.7.1 ATHERECTOMY DEVICES 150 9.7.1.1 Increase in incidence of atherosclerosis to drive market 150 9.7.2 THROMBECTOMY DEVICES 152 9.7.2.1 Growing DVT incidence to drive adoption of thrombectomy devices 152 9.8 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 154 9.8.1 EMBOLIC PROTECTION DEVICES 156 9.8.1.1 Investments in technological advancements and growing regulatory approvals to drive market 156   9.8.2 CHRONIC TOTAL OCCLUSION DEVICES 158 9.8.2.1 Rise in support for device development especially in addressing longstanding plaque buildup to drive market 158 9.9 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 160 9.9.1 GUIDEWIRES 162 9.9.1.1 Higher success rate during stenting and endovascular aneurysm repair contribute to largest market share 162 9.9.2 VASCULAR CLOSURE DEVICES 164 9.9.2.1 Technological advancements and minimized duration of hospital stay to support demand 164 9.9.3 INTRODUCER SHEATHS 166 9.9.3.1 Potential for reducing arterial damage during interventional procedures to drive adoption 166 9.9.4 BALLOON INFLATION DEVICES 168 9.9.4.1 Integrated technologies and rising number of target procedures to propel adoption 168 10 PERIPHERAL VASCULAR DEVICES MARKET, BY END USER 170 10.1 INTRODUCTION 171 10.2 HOSPITALS 171 10.2.1 ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE SEGMENT GROWTH 171 10.2.2 LARGE CHAIN HOSPITALS 174 10.2.2.1 Strong infrastructure and integrated networks driving dominance in complex peripheral vascular procedures 174 10.2.3 STANDALONE HOSPITAL FACILITIES 176 10.2.3.1 Expanding accessibility and cost-effective care to support peripheral vascular procedure volumes 176 10.3 AMBULATORY SURGICAL CENTERS 178 10.3.1 FASTER PROCEDURE TIME AND LOWER INFECTION RATES TO DRIVE SEGMENT GROWTH 178 10.4 OTHER END USERS 180 11 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION 182 11.1 INTRODUCTION 183 11.2 NORTH AMERICA 184 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 184 11.2.2 NORTH AMERICA ANGIOPLASTY STENTS MARKET: VOLUME ANALYSIS, BY TYPE 186 11.2.3 US 190 11.2.3.1 Favorable reimbursement scenario to contribute to market growth 190 11.2.4 CANADA 195 11.2.4.1 Increasing cases of chronic conditions to fuel market 195   11.3 EUROPE 200 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 200 11.3.2 EUROPE ANGIOPLASTY STENTS MARKET: VOLUME ANALYSIS, BY TYPE 202 11.3.3 GERMANY 206 11.3.3.1 Statutory health insurance policy to support market growth 206 11.3.4 FRANCE 211 11.3.4.1 Growing geriatric population to drive market 211 11.3.5 UK 216 11.3.5.1 Increasing volume of coronary angioplasty procedures to sustain market growth 216 11.3.6 SPAIN 221 11.3.6.1 Growing cases of diabetes and obesity to boost market 221 11.3.7 ITALY 226 11.3.7.1 Increasing prevalence of atherosclerotic cardiovascular disease to spur market growth 226 11.3.8 REST OF EUROPE 231 11.4 ASIA PACIFIC 236 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 237 11.4.2 ASIA PACIFIC ANGIOPLASTY STENTS MARKET: VOLUME ANALYSIS, BY TYPE 239 11.4.3 JAPAN 243 11.4.3.1 Large geriatric population to ensure sustained demand 243 11.4.4 CHINA 248 11.4.4.1 Growing incidence of lifestyle diseases to fuel market 248 11.4.5 INDIA 253 11.4.5.1 Rising prevalence of target diseases and growing healthcare expenditure to propel market 253 11.4.6 AUSTRALIA 258 11.4.6.1 High prevalence of cardiovascular and peripheral artery diseases to drive market 258 11.4.7 SOUTH KOREA 263 11.4.7.1 Rising rates of chronic diseases to boost market 263 11.4.8 REST OF ASIA PACIFIC 268 11.5 LATIN AMERICA 272 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 273 11.5.2 LATIN AMERICA ANGIOPLASTY STENTS MARKET: VOLUME ANALYSIS, BY TYPE 275 11.5.3 BRAZIL 278 11.5.3.1 Rising healthcare expenditure to aid market growth 278 11.5.4 MEXICO 283 11.5.4.1 Increasing prevalence of cardiovascular diseases to spur market growth 283 11.5.5 COLOMBIA 288 11.5.5.1 Growing incidence of peripheral artery diseases to expedite market growth 288   11.5.6 ARGENTINA 293 11.5.6.1 Increasing prevalence of peripheral artery diseases to support market growth 293 11.5.7 REST OF LATIN AMERICA 298 11.6 MIDDLE EAST & AFRICA 303 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 303 11.6.2 MIDDLE EAST & AFRICA ANGIOPLASTY STENTS MARKET: VOLUME ANALYSIS, BY TYPE 305 11.6.3 GCC COUNTRIES 309 11.6.3.1 Kingdom of Saudi Arabia (KSA) 314 11.6.3.1.1 Rising diabetes prevalence and strong government healthcare investments to drive market 314 11.6.3.2 United Arab Emirates (UAE) 319 11.6.3.2.1 Advanced healthcare infrastructure and growing medical tourism to accelerate peripheral vascular devices adoption 319 11.6.4 REST OF GCC COUNTRIES 324 11.6.5 REST OF MIDDLE EAST & AFRICA 328 12 COMPETITIVE LANDSCAPE 334 12.1 INTRODUCTION 334 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 334 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 334 12.3 REVENUE ANALYSIS 336 12.4 MARKET SHARE ANALYSIS 336 12.4.1 GLOBAL: PERIPHERAL VASCULAR DEVICES MARKET SHARE ANALYSIS, 2025 337 12.4.2 US: PERIPHERAL VASCULAR DEVICES MARKET SHARE ANALYSIS, 2025 339 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 339 12.5.1 STARS 339 12.5.2 EMERGING LEADERS 339 12.5.3 PERVASIVE PLAYERS 339 12.5.4 PARTICIPANTS 340 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 341 12.5.5.1 Company footprint 341 12.5.5.2 Regional footprint 342 12.5.5.3 Product type footprint 343 12.5.5.4 End user footprint 344 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 345 12.6.1 PROGRESSIVE COMPANIES 345 12.6.2 DYNAMIC COMPANIES 345 12.6.3 RESPONSIVE COMPANIES 345 12.6.4 STARTING BLOCKS 345 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 347   12.7 BRAND/PRODUCT COMPARISON 349 12.8 COMPANY VALUATION AND FINANCIAL METRICS 349 12.8.1 FINANCIAL METRICS 349 12.8.2 COMPANY VALUATION 350 12.9 COMPETITIVE SCENARIO 350 12.9.1 PRODUCT LAUNCHES AND APPROVALS 351 12.9.2 DEALS 352 13 COMPANY PROFILES 355 13.1 KEY PLAYERS 355 13.1.1 BOSTON SCIENTIFIC CORPORATION 355 13.1.1.1 Business overview 355 13.1.1.2 Products offered 356 13.1.1.3 Recent developments 358 13.1.1.3.1 Product approvals 358 13.1.1.3.2 Deals 359 13.1.1.3.3 Other developments 360 13.1.1.4 MnM view 360 13.1.1.4.1 Right to win 360 13.1.1.4.2 Strategic choices 360 13.1.1.4.3 Weaknesses and competitive threats 360 13.1.2 BECTON, DICKINSON AND COMPANY 361 13.1.2.1 Business overview 361 13.1.2.2 Products offered 362 13.1.2.3 Recent developments 364 13.1.2.3.1 Product launches and approvals 364 13.1.2.3.2 Deals 365 13.1.2.3.3 Expansions 366 13.1.2.3.4 Other developments 366 13.1.2.4 MnM view 367 13.1.2.4.1 Right to win 367 13.1.2.4.2 Strategic choices 367 13.1.2.4.3 Weaknesses and competitive threats 367 13.1.3 ABBOTT LABORATORIES 368 13.1.3.1 Business overview 368 13.1.3.2 Products offered 369 13.1.3.3 Recent developments 371 13.1.3.3.1 Product launches 371 13.1.3.3.2 Deals 372 13.1.3.3.3 Expansions 372   13.1.3.4 MnM view 373 13.1.3.4.1 Right to win 373 13.1.3.4.2 Strategic choices made 373 13.1.3.4.3 Weaknesses and competitive threats 373 13.1.4 CARDINAL HEALTH, INC. 374 13.1.4.1 Business overview 374 13.1.4.2 Products offered 375 13.1.4.3 Recent developments 377 13.1.4.3.1 Product launches 377 13.1.4.3.2 Deals 377 13.1.4.3.3 Expansions 378 13.1.4.4 MnM view 378 13.1.4.4.1 Right to win 378 13.1.4.4.2 Strategic choices 379 13.1.4.4.3 Weaknesses and competitive threats 379 13.1.5 KONINKLIJKE PHILIPS N.V. 380 13.1.5.1 Business overview 380 13.1.5.2 Products offered 381 13.1.5.3 Recent developments 382 13.1.5.3.1 Product approvals 382 13.1.5.3.2 Deals 383 13.1.5.3.3 Expansions 383 13.1.5.4 MnM view 384 13.1.5.4.1 Right to win 384 13.1.5.4.2 Strategic choices 384 13.1.5.4.3 Weaknesses and competitive threats 384 13.1.6 TERUMO CORPORATION 385 13.1.6.1 Business overview 385 13.1.6.2 Products offered 386 13.1.6.3 Recent developments 387 13.1.6.3.1 Product launches 387 13.1.6.3.2 Deals 388 13.1.6.3.3 Expansions 389 13.1.7 MERIT MEDICAL SYSTEMS, INC. 390 13.1.7.1 Business overview 390 13.1.7.2 Products offered 391 13.1.7.3 Recent developments 392 13.1.7.3.1 Product launches 392 13.1.7.3.2 Deals 392   13.1.8 B. BRAUN SE 394 13.1.8.1 Business overview 394 13.1.8.2 Products offered 395 13.1.8.3 Recent developments 397 13.1.8.3.1 Product approvals 397 13.1.9 MEDTRONIC 398 13.1.9.1 Business overview 398 13.1.9.2 Products offered 399 13.1.9.3 Recent developments 401 13.1.9.3.1 Product launches and approvals 401 13.1.9.3.2 Deals 402 13.1.10 PENUMBRA, INC. 403 13.1.10.1 Business overview 403 13.1.10.2 Products offered 404 13.1.10.3 Recent developments 405 13.1.10.3.1 Product launches and approvals 405 13.1.11 STRYKER CORPORATION 406 13.1.11.1 Business overview 406 13.1.11.2 Products offered 407 13.1.11.3 Recent developments 408 13.1.11.3.1 Deals 408 13.1.12 CORDIS 409 13.1.12.1 Business overview 409 13.1.12.2 Products offered 409 13.1.12.3 Recent developments 411 13.1.12.3.1 Product approvals 411 13.1.12.3.2 Deals 411 13.1.13 COOK 412 13.1.13.1 Business overview 412 13.1.13.2 Products offered 412 13.1.13.3 Recent developments 414 13.1.13.3.1 Deals 414 13.1.14 W. L. GORE & ASSOCIATES, INC. 415 13.1.14.1 Business overview 415 13.1.14.2 Products offered 415 13.1.14.3 Recent developments 416 13.1.14.3.1 Product approvals 416 13.1.15 BIOSENSORS INTERNATIONAL GROUP, LTD. 417 13.1.15.1 Business overview 417 13.1.15.2 Products offered 417   13.1.16 IVASCULAR 418 13.1.16.1 Business overview 418 13.1.16.2 Products offered 418 13.1.17 BIOTRONIK 419 13.1.17.1 Business overview 419 13.1.17.2 Products offered 419 13.1.17.3 Recent developments 420 13.1.17.3.1 Product launches 420 13.1.18 ENDOLOGIX 421 13.1.18.1 Business overview 421 13.1.18.2 Products offered 421 13.1.19 ENDOCOR GMBH & CO., KG 422 13.1.19.1 Business overview 422 13.1.19.2 Products offered 422 13.2 OTHER PLAYERS 423 13.2.1 MERIL LIFE SCIENCES PVT. LTD. 423 13.2.2 ALVIMEDICA 424 13.2.3 CARDIONOVUM GMBH 425 13.2.4 SMT 425 13.2.5 MEDINOL 426 13.2.6 ANDRAMED GMBH 426 13.2.7 REX MEDICAL 427 13.2.8 QMD 427 13.2.9 BROSMED MEDICAL CO., LTD. 428 13.2.10 ELIXIR MEDICAL 428 14 RESEARCH METHODOLOGY 429 14.1 RESEARCH DATA 429 14.1.1 SECONDARY DATA 429 14.1.1.1 Key data from secondary sources 431 14.1.2 PRIMARY DATA 431 14.1.2.1 Key data from primary sources 433 14.1.2.2 Key industry insights 433 14.1.2.3 Key industry insights 434 14.2 MARKET SIZE ESTIMATION 435 14.3 GROWTH FORECAST 439 14.3.1 KEY INDUSTRY INSIGHTS 440 14.4 MARKET BREAKDOWN AND DATA TRIANGULATION 441 14.5 RESEARCH ASSUMPTIONS 442 14.6 RISK ASSESSMENT 442 14.7 RESEARCH LIMITATIONS 442 15 APPENDIX 443 15.1 DISCUSSION GUIDE 443 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 448 15.3 CUSTOMIZATION OPTIONS 450 15.3.1 PRODUCT ANALYSIS 450 15.3.2 US: END-USER ANALYSIS 450 15.3.3 GEOGRAPHIC ANALYSIS 450 15.3.4 COMPANY INFORMATION 450 15.3.5 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 450 15.3.6 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT TYPE 450 15.3.7 MARKET SHARE ANALYSIS, BY PRODUCT TYPE (TOP FIVE PLAYERS) 450 15.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 450 15.4 RELATED REPORTS 451 15.5 AUTHOR DETAILS 452
圖表清單 List of Tables & Figures
TABLE 1 INCLUSIONS & EXCLUSIONS 39 TABLE 2 STANDARD CURRENCY CONVERSION RATES 40 TABLE 3 GLOBAL GERIATRIC POPULATION TRENDS (2015 VS. 2030): REGIONAL BREAKDOWN 51 TABLE 4 US: REIMBURSEMENT FOR PERIPHERAL VASCULAR PROCEDURES, 2026 (USD) 52 TABLE 5 PRODUCT APPROVALS IN PERIPHERAL VASCULAR DEVICES MARKET, 2023–2024 52 TABLE 6 DIABETES POPULATION, BY REGION, 2024 VS. 2050 53 TABLE 7 TOP 10 COUNTRIES WITH HIGHEST SMOKING RATE, 2025 54 TABLE 8 OBESITY RATE IN DEVELOPING COUNTRIES, 2026 55 TABLE 9 PRODUCT FAILURES AND RECALLS 56 TABLE 10 UNMET NEEDS AND WHITE SPACES 59 TABLE 11 INTERCONNECTED MARKETS 60 TABLE 12 CROSS-SECTOR OPPORTUNITIES 60 TABLE 13 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 61 TABLE 14 IMPACT OF PORTER’S FIVE FORCES ON PERIPHERAL VASCULAR DEVICES MARKET 62 TABLE 15 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 (USD) 72 TABLE 16 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 (USD) 72 TABLE 17 IMPORT DATA FOR HS CODE 901839-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 74 TABLE 18 EXPORT DATA FOR HS CODE 901839-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 76 TABLE 19 PERIPHERAL VASCULAR DEVICES MARKET: LIST OF KEY CONFERENCES AND EVENTS, 2026–2027 77 TABLE 20 US ADJUSTED RECIPROCAL TARIFF RATES 81 TABLE 21 PERIPHERAL VASCULAR DEVICES MARKET: TECHNOLOGY/PRODUCT ROADMAP (2026–2035) 89 TABLE 22 PERIPHERAL VASCULAR DEVICES MARKET: LIST OF MAJOR PATENTS, JANUARY 2023–FEBRUARY 2026 92 TABLE 23 AI INTEGRATION: PERIPHERAL VASCULAR DEVICES MARKET 95 TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PERIPHERAL VASCULAR DEVICES 103 TABLE 30 KEY BUYING CRITERIA FOR TOP THREE END USERS 104 TABLE 31 PERIPHERAL VASCULAR DEVICES MARKET: UNMET NEEDS IN KEY END-USE SETTINGS 106 TABLE 32 PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 109 TABLE 33 ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 110 TABLE 34 ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 110 TABLE 35 ANGIOPLASTY STENTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 111 TABLE 36 DRUG-ELUTING STENTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 113 TABLE 37 BARE-METAL STENTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 115 TABLE 38 BARE-METAL STENTS MARKET, BY DELIVERY PLATFORM, 2024–2031 (USD MILLION) 116 TABLE 39 BALLOON-EXPANDABLE STENTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 117 TABLE 40 SELF-EXPANDABLE STENTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 119 TABLE 41 EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 120 TABLE 42 EVAR STENT GRAFTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 121 TABLE 43 AAA STENT GRAFTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 123 TABLE 44 TAA STENT GRAFTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 125 TABLE 45 CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 126 TABLE 46 CATHETERS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 127 TABLE 47 ANGIOGRAPHY CATHETERS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 129 TABLE 48 GUIDING CATHETERS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 131 TABLE 49 IVUS/OCT CATHETERS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 133 TABLE 50 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 134 TABLE 51 INFERIOR VENA CAVA FILTERS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 135 TABLE 52 RETRIEVABLE INFERIOR VENA CAVA FILTERS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 137 TABLE 53 PERMANENT INFERIOR VENA CAVA FILTERS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 139 TABLE 54 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 140 TABLE 55 ANGIOPLASTY BALLOONS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 141 TABLE 56 OLD/NORMAL BALLOONS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 143 TABLE 57 DRUG-ELUTING BALLOONS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 145 TABLE 58 CUTTING & SCORING BALLOONS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 147 TABLE 59 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 148 TABLE 60 PLAQUE MODIFICATION DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 149 TABLE 61 ATHERECTOMY DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 151 TABLE 62 THROMBECTOMY DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 153 TABLE 63 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 64 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 155 TABLE 65 EMBOLIC PROTECTION DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 157 TABLE 66 CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 159 TABLE 67 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 160 TABLE 68 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 161 TABLE 69 GUIDEWIRES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 163 TABLE 70 VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 165 TABLE 71 INTRODUCER SHEATHS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 167 TABLE 72 BALLOON INFLATION DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 169 TABLE 73 PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 171 TABLE 74 PERIPHERAL VASCULAR DEVICES MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 75 PERIPHERAL VASCULAR DEVICES MARKET FOR HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 173 TABLE 76 PERIPHERAL VASCULAR DEVICES MARKET FOR LARGE CHAIN HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 175 TABLE 77 PERIPHERAL VASCULAR DEVICES MARKET FOR STANDALONE HOSPITAL FACILITIES SEGMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 177 TABLE 78 PERIPHERAL VASCULAR DEVICES MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 179 TABLE 79 PERIPHERAL VASCULAR DEVICES MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 181 TABLE 80 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 81 NORTH AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 82 NORTH AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 185 TABLE 83 NORTH AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 84 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 186 TABLE 85 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 86 NORTH AMERICA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 87 NORTH AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 88 NORTH AMERICA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 89 NORTH AMERICA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 90 NORTH AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 91 NORTH AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 92 NORTH AMERICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 93 NORTH AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 189 TABLE 94 NORTH AMERICA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 95 US: MACROECONOMIC INDICATORS 190 TABLE 96 US: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 191 TABLE 97 US: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 98 US: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 99 US: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 100 US: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 101 US: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 102 US: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 103 US: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 104 US: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 105 US: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 106 US: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 194 TABLE 107 US: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 108 CANADA: MACROECONOMIC INDICATORS 195 TABLE 109 CANADA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 196 TABLE 110 CANADA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 111 CANADA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 112 CANADA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 113 CANADA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 114 CANADA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 115 CANADA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 116 CANADA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 117 CANADA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 118 CANADA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 119 CANADA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 199 TABLE 120 CANADA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 121 EUROPE: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 122 EUROPE: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 201 TABLE 123 EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 124 EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 202 TABLE 125 EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 126 EUROPE: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 127 EUROPE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 128 EUROPE: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 129 EUROPE: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 130 EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 131 EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 132 EUROPE: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 133 EUROPE: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 205 TABLE 134 EUROPE: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 135 GERMANY: MACROECONOMIC INDICATORS 206 TABLE 136 GERMANY: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 207 TABLE 137 GERMANY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 138 GERMANY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 139 GERMANY: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 140 GERMANY: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 141 GERMANY: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 142 GERMANY: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 143 GERMANY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 144 GERMANY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 145 GERMANY: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 146 GERMANY: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 147 GERMANY: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 148 FRANCE: MACROECONOMIC INDICATORS 211 TABLE 149 FRANCE: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 212 TABLE 150 FRANCE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 151 FRANCE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 152 FRANCE: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 153 FRANCE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 154 FRANCE: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 155 FRANCE: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 156 FRANCE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 157 FRANCE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 158 FRANCE: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 159 FRANCE: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 215 TABLE 160 FRANCE: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 161 UK: MACROECONOMIC INDICATORS 216 TABLE 162 UK: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 217 TABLE 163 UK: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 164 UK: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 165 UK: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 166 UK: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 167 UK: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 168 UK: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 169 UK: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 170 UK: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 171 UK: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 172 UK: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 173 UK: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 174 SPAIN: MACROECONOMIC INDICATORS 222 TABLE 175 SPAIN: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 222 TABLE 176 SPAIN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 177 SPAIN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 178 SPAIN: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 179 SPAIN: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 180 SPAIN: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 181 SPAIN: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 182 SPAIN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 183 SPAIN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 184 SPAIN: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 185 SPAIN: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 226 TABLE 186 SPAIN: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 187 ITALY: MACROECONOMIC INDICATORS 227 TABLE 188 ITALY: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 227 TABLE 189 ITALY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 190 ITALY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 191 ITALY: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 192 ITALY: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 193 ITALY: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 194 ITALY: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 195 ITALY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 196 ITALY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 197 ITALY: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 198 ITALY: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 231 TABLE 199 ITALY: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 200 REST OF EUROPE: PERCENTAGE OF GERIATRIC POPULATION TO TOTAL POPULATION, BY COUNTRY, 2015 VS. 2030 232 TABLE 201 REST OF EUROPE: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 232 TABLE 202 REST OF EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 203 REST OF EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 204 REST OF EUROPE: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 205 REST OF EUROPE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 206 REST OF EUROPE: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 207 REST OF EUROPE: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 208 REST OF EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 209 REST OF EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 210 REST OF EUROPE: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 211 REST OF EUROPE: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 236 TABLE 212 REST OF EUROPE: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 213 ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 214 ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 238 TABLE 215 ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 216 ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 239 TABLE 217 ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 218 ASIA PACIFIC: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 219 ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 220 ASIA PACIFIC: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 221 ASIA PACIFIC: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 222 ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 223 ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 224 ASIA PACIFIC: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 225 ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 226 ASIA PACIFIC: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 227 JAPAN: MACROECONOMIC INDICATORS 243 TABLE 228 JAPAN: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 244 TABLE 229 JAPAN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 230 JAPAN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 231 JAPAN: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 232 JAPAN: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 233 JAPAN: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 234 JAPAN: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 235 JAPAN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 236 JAPAN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 237 JAPAN: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 238 JAPAN: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 247 TABLE 239 JAPAN: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 240 CHINA: MACROECONOMIC INDICATORS 248 TABLE 241 CHINA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 249 TABLE 242 CHINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 243 CHINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 244 CHINA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 245 CHINA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 246 CHINA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 247 CHINA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 248 CHINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 249 CHINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 250 CHINA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 251 CHINA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 252 CHINA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 253 INDIA: MACROECONOMIC INDICATORS 253 TABLE 254 INDIA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 254 TABLE 255 INDIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 256 INDIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 257 INDIA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 258 INDIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 259 INDIA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 260 INDIA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 261 INDIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 262 INDIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 263 INDIA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 264 INDIA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 265 INDIA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 266 AUSTRALIA: MACROECONOMIC INDICATORS 258 TABLE 267 AUSTRALIA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 259 TABLE 268 AUSTRALIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 269 AUSTRALIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 270 AUSTRALIA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 271 AUSTRALIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 272 AUSTRALIA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 273 AUSTRALIA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 274 AUSTRALIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 275 AUSTRALIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 276 AUSTRALIA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 277 AUSTRALIA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 262 TABLE 278 AUSTRALIA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 279 SOUTH KOREA: MACROECONOMIC INDICATORS 263 TABLE 280 SOUTH KOREA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 264 TABLE 281 SOUTH KOREA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 282 SOUTH KOREA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 283 SOUTH KOREA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 284 SOUTH KOREA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 285 SOUTH KOREA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 286 SOUTH KOREA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 287 SOUTH KOREA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 288 SOUTH KOREA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 289 SOUTH KOREA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 290 SOUTH KOREA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 267 TABLE 291 SOUTH KOREA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 292 REST OF ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 268 TABLE 293 REST OF ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 294 REST OF ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 295 REST OF ASIA PACIFIC: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 296 REST OF ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 297 REST OF ASIA PACIFIC: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 298 REST OF ASIA PACIFIC: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 299 REST OF ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 300 REST OF ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 301 REST OF ASIA PACIFIC: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 302 REST OF ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 303 REST OF ASIA PACIFIC: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 304 LATIN AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 273 TABLE 305 LATIN AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 274 TABLE 306 LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 307 LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 275 TABLE 308 LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 309 LATIN AMERICA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 310 LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 311 LATIN AMERICA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 312 LATIN AMERICA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 313 LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 314 LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 315 LATIN AMERICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 316 LATIN AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 278 TABLE 317 LATIN AMERICA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 318 BRAZIL: MACROECONOMIC INDICATORS 279 TABLE 319 BRAZIL: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 279 TABLE 320 BRAZIL: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 321 BRAZIL: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 322 BRAZIL: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 323 BRAZIL: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 324 BRAZIL: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 325 BRAZIL: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 326 BRAZIL: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 327 BRAZIL: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 328 BRAZIL: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 329 BRAZIL: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 283 TABLE 330 BRAZIL: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 331 MEXICO: MACROECONOMIC INDICATORS 284 TABLE 332 MEXICO: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 284 TABLE 333 MEXICO: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 334 MEXICO: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 335 MEXICO: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 336 MEXICO: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 337 MEXICO: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 338 MEXICO: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 339 MEXICO: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 340 MEXICO: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 341 MEXICO: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 342 MEXICO: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 288 TABLE 343 MEXICO: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 344 COLOMBIA: MACROECONOMIC INDICATORS 289 TABLE 345 COLOMBIA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 289 TABLE 346 COLOMBIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 347 COLOMBIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 348 COLOMBIA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 349 COLOMBIA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 350 COLOMBIA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 351 COLOMBIA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 352 COLOMBIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 353 COLOMBIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 354 COLOMBIA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 355 COLOMBIA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 293 TABLE 356 COLOMBIA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 357 ARGENTINA: MACROECONOMIC INDICATORS 294 TABLE 358 ARGENTINA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 294 TABLE 359 ARGENTINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 360 ARGENTINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 361 ARGENTINA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 362 ARGENTINA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 363 ARGENTINA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 364 ARGENTINA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 365 ARGENTINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 366 ARGENTINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 367 ARGENTINA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 368 ARGENTINA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 298 TABLE 369 ARGENTINA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 370 REST OF LATIN AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 299 TABLE 371 REST OF LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 372 REST OF LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 373 REST OF LATIN AMERICA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 374 REST OF LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 375 REST OF LATIN AMERICA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 376 REST OF LATIN AMERICA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 377 REST OF LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 378 REST OF LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 379 REST OF LATIN AMERICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 380 REST OF LATIN AMERICA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 302 TABLE 381 REST OF LATIN AMERICA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 382 MIDDLE EAST & AFRICA: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 304 TABLE 383 MIDDLE EAST & AFRICA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 304 TABLE 384 MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 385 MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 305 TABLE 386 MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 387 MIDDLE EAST & AFRICA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 388 MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 389 MIDDLE EAST & AFRICA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 390 MIDDLE EAST & AFRICA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 391 MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 392 MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 393 MIDDLE EAST & AFRICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 394 MIDDLE EAST & AFRICA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 308 TABLE 395 MIDDLE EAST & AFRICA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 396 GCC COUNTRIES: PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 309 TABLE 397 GCC COUNTRIES: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 310 TABLE 398 GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 399 GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 400 GCC COUNTRIES: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 401 GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 402 GCC COUNTRIES: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 403 GCC COUNTRIES: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 404 GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 405 GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 406 GCC COUNTRIES: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 407 GCC COUNTRIES: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 313 TABLE 408 GCC COUNTRIES: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 409 KSA: MACROECONOMIC INDICATORS 314 TABLE 410 KSA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 315 TABLE 411 KSA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 412 KSA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 413 KSA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 414 KSA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 415 KSA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 416 KSA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 417 KSA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 418 KSA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 419 KSA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 420 KSA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 421 KSA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 422 UAE: MACROECONOMIC INDICATORS 319 TABLE 423 UAE: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 320 TABLE 424 UAE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 425 UAE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 426 UAE: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 427 UAE: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 428 UAE: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 429 UAE: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 430 UAE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 431 UAE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 432 UAE: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 433 UAE: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 323 TABLE 434 UAE: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 435 REST OF GCC COUNTRIES: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 324 TABLE 436 REST OF GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 437 REST OF GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 438 REST OF GCC COUNTRIES: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 439 REST OF GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 440 REST OF GCC COUNTRIES: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 441 REST OF GCC COUNTRIES: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 442 REST OF GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 443 REST OF GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 444 REST OF GCC COUNTRIES: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 445 REST OF GCC COUNTRIES: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 328 TABLE 446 REST OF GCC COUNTRIES: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 328 TABLE 447 REST OF MIDDLE EAST & AFRICA: PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 329 TABLE 448 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 449 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 450 REST OF MIDDLE EAST & AFRICA: BARE-METAL STENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 451 REST OF MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 452 REST OF MIDDLE EAST & AFRICA: EVAR STENT GRAFTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 453 REST OF MIDDLE EAST & AFRICA: INFERIOR VENA CAVA FILTERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 454 REST OF MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 455 REST OF MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 456 REST OF MIDDLE EAST & AFRICA: OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 457 REST OF MIDDLE EAST & AFRICA: PERIPHERAL VASCULAR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 332 TABLE 458 REST OF MIDDLE EAST & AFRICA: HOSPITALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 459 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PERIPHERAL VASCULAR DEVICES MARKET 334 TABLE 460 PERIPHERAL VASCULAR DEVICES MARKET: DEGREE OF COMPETITION 337 TABLE 461 PERIPHERAL VASCULAR DEVICES MARKET: REGIONAL FOOTPRINT, 2025 342 TABLE 462 PERIPHERAL VASCULAR DEVICES MARKET: PRODUCT TYPE FOOTPRINT, 2025 343 TABLE 463 PERIPHERAL VASCULAR DEVICES MARKET: END USER FOOTPRINT, 2025 344 TABLE 464 PERIPHERAL VASCULAR DEVICES MARKET: KEY STARTUPS/SMES, 2025 347 TABLE 465 PERIPHERAL VASCULAR DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2025 348 TABLE 466 PERIPHERAL VASCULAR DEVICES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–MARCH 2026 351 TABLE 467 PERIPHERAL VASCULAR DEVICES MARKET: DEALS, JANUARY 2023–MARCH 2026 352 TABLE 468 PERIPHERAL VASCULAR DEVICES MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026 353 TABLE 469 PERIPHERAL VASCULAR DEVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 354 TABLE 470 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 355 TABLE 471 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 356 TABLE 472 BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS 358 TABLE 473 BOSTON SCIENTIFIC CORPORATION: DEALS 359 TABLE 474 BOSTON SCIENTIFIC CORPORATION: OTHER DEVELOPMENTS 360 TABLE 475 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 361 TABLE 476 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 362 TABLE 477 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS 364 TABLE 478 BECTON, DICKINSON AND COMPANY: DEALS 365 TABLE 479 BECTON, DICKINSON AND COMPANY: EXPANSIONS 366 TABLE 480 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS 366 TABLE 481 ABBOTT LABORATORIES: COMPANY OVERVIEW 368 TABLE 482 ABBOTT LABORATORIES: PRODUCTS OFFERED 369 TABLE 483 ABBOTT LABORATORIES: PRODUCT LAUNCHES 371 TABLE 484 ABBOTT LABORATORIES: DEALS 372 TABLE 485 ABBOTT LABORATORIES: EXPANSIONS 372 TABLE 486 CARDINAL HEALTH, INC.: COMPANY OVERVIEW 374 TABLE 487 CARDINAL HEALTH, INC.: PRODUCTS OFFERED 375 TABLE 488 CARDINAL HEALTH, INC.: PRODUCT LAUNCHES 377 TABLE 489 CARDINAL HEALTH, INC.: DEALS 377 TABLE 490 CARDINAL HEALTH, INC.: EXPANSIONS 378 TABLE 491 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 380 TABLE 492 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 381 TABLE 493 KONINKLIJKE PHILIPS N.V.: PRODUCT APPROVALS 382 TABLE 494 KONINKLIJKE PHILIPS N.V.: DEALS 383 TABLE 495 KONINKLIJKE PHILIPS N.V.: EXPANSIONS 383 TABLE 496 TERUMO CORPORATION: COMPANY OVERVIEW 385 TABLE 497 TERUMO CORPORATION: PRODUCTS OFFERED 386 TABLE 498 TERUMO CORPORATION: PRODUCT LAUNCHES 387 TABLE 499 TERUMO CORPORATION: DEALS 388 TABLE 500 TERUMO CORPORATION: EXPANSIONS 389 TABLE 501 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW 390 TABLE 502 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED 391 TABLE 503 MERIT MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES 392 TABLE 504 MERIT MEDICAL SYSTEMS, INC.: DEALS 392 TABLE 505 B. BRAUN SE: COMPANY OVERVIEW 394 TABLE 506 B. BRAUN SE: PRODUCTS OFFERED 395 TABLE 507 B. BRAUN SE: PRODUCT APPROVALS 397 TABLE 508 MEDTRONIC: COMPANY OVERVIEW 398 TABLE 509 MEDTRONIC: PRODUCTS OFFERED 399 TABLE 510 MEDTRONIC: PRODUCT LAUNCHES AND APPROVALS 401 TABLE 511 MEDTRONIC: DEALS 402 TABLE 512 PENUMBRA, INC.: COMPANY OVERVIEW 403 TABLE 513 PENUMBRA, INC.: PRODUCTS OFFERED 404 TABLE 514 PENUMBRA, INC.: PRODUCT LAUNCHES AND APPROVALS 405 TABLE 515 STRYKER CORPORATION: COMPANY OVERVIEW 406 TABLE 516 STRYKER CORPORATION: PRODUCTS OFFERED 407 TABLE 517 STRYKER CORPORATION: DEALS 408 TABLE 518 CORDIS: COMPANY OVERVIEW 409 TABLE 519 CORDIS: PRODUCTS OFFERED 409 TABLE 520 CORDIS: PRODUCT APPROVALS 411 TABLE 521 CORDIS: DEALS 411 TABLE 522 COOK: COMPANY OVERVIEW 412 TABLE 523 COOK: PRODUCTS OFFERED 412 TABLE 524 COOK: DEALS 414 TABLE 525 W. L. GORE & ASSOCIATES, INC.: COMPANY OVERVIEW 415 TABLE 526 W. L. GORE & ASSOCIATES, INC.: PRODUCTS OFFERED 415 TABLE 527 W. L. GORE & ASSOCIATES, INC: PRODUCT APPROVALS 416 TABLE 528 BIOSENSORS INTERNATIONAL GROUP, LTD.: COMPANY OVERVIEW 417 TABLE 529 BIOSENSORS INTERNATIONAL GROUP, LTD.: PRODUCTS OFFERED 417 TABLE 530 IVASCULAR: COMPANY OVERVIEW 418 TABLE 531 IVASCULAR: PRODUCTS OFFERED 418 TABLE 532 BIOTRONIK: COMPANY OVERVIEW 419 TABLE 533 BIOTRONIK: PRODUCTS OFFERED 419 TABLE 534 BIOTRONIK: PRODUCT LAUNCHES 420 TABLE 535 ENDOLOGIX: COMPANY OVERVIEW 421 TABLE 536 ENDOLOGIX: PRODUCTS OFFERED 421 TABLE 537 ENDOCOR GMBH & CO., KG: COMPANY OVERVIEW 422 TABLE 538 ENDOCOR GMBH & CO., KG: PRODUCTS OFFERED 422 TABLE 539 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW 423 TABLE 540 ALVIMEDICA: COMPANY OVERVIEW 424 TABLE 541 CARDIONOVUM GMBH: COMPANY OVERVIEW 425 TABLE 542 SMT: COMPANY OVERVIEW 425 TABLE 543 MEDINOL: COMPANY OVERVIEW 426 TABLE 544 ANDRAMED GMBH: COMPANY OVERVIEW 426 TABLE 545 REX MEDICAL: COMPANY OVERVIEW 427 TABLE 546 QMD: COMPANY OVERVIEW 427 TABLE 547 BROSMED MEDICAL CO., LTD.: COMPANY OVERVIEW 428 TABLE 548 ELIXIR MEDICAL: COMPANY OVERVIEW 428 FIGURE 1 MARKETS COVERED 38 FIGURE 2 STUDY YEARS 39 FIGURE 3 MARKET SCENARIO 42 FIGURE 4 GLOBAL PERIPHERAL VASCULAR DEVICES MARKET, 2024–2031 43 FIGURE 5 PERIPHERAL VASCULAR DEVICES MARKET: MAJOR STRATEGIES ADOPTED BY KEY PLAYERS, 2022–2025 43 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PERIPHERAL VASCULAR DEVICES MARKET 44 FIGURE 7 PERIPHERAL VASCULAR DEVICES MARKET: HIGH-GROWTH SEGMENTS, 2026–2031 45 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PERIPHERAL VASCULAR DEVICES MARKET DURING FORECAST PERIOD 46 FIGURE 9 RISING PREVALENCE OF PERIPHERAL ARTERY DISEASE (PAD) TO DRIVE MARKET 47 FIGURE 10 ANGIOPLASTY STENT PRODUCTS AND CHINA LED RESPECTIVE MARKET SEGMENTS IN 2025 48 FIGURE 11 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49 FIGURE 12 INDIA TO REGISTER HIGHER GROWTH RATES THAN EMERGING ECONOMIES DURING FORECAST PERIOD 49 FIGURE 13 PERIPHERAL VASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 FIGURE 14 PERIPHERAL VASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 63 FIGURE 15 PERIPHERAL VASCULAR DEVICES MARKET: SUPPLY CHAIN 69 FIGURE 16 PERIPHERAL VASCULAR DEVICES MARKET: VALUE CHAIN ANALYSIS (2025) 70 FIGURE 17 PERIPHERAL VASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS 71 FIGURE 18 IMPORT DATA FOR HS CODE 901839-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 74 FIGURE 19 EXPORT DATA FOR HS CODE 901839-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 75 FIGURE 20 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 78 FIGURE 21 INVESTMENT/VENTURE CAPITAL SCENARIO IN PERIPHERAL VASCULAR DEVICES MARKET, 2021–2025 79 FIGURE 22 PATENTS APPLIED AND GRANTED, 2015–2025 91 FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR PERIPHERAL VASCULAR PATENTS, 2015–2025 92 FIGURE 24 PERIPHERAL VASCULAR DEVICES MARKET: DECISION-MAKING FACTORS 102 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PERIPHERAL VASCULAR DEVICES 103 FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 104 FIGURE 27 ADOPTION BARRIERS AND INTERNAL CHALLENGES 105 FIGURE 28 NORTH AMERICA: PERIPHERAL VASCULAR DEVICES MARKET SNAPSHOT 184 FIGURE 29 ASIA PACIFIC: PERIPHERAL VASCULAR DEVICES MARKET SNAPSHOT 237 FIGURE 30 REVENUE ANALYSIS FOR KEY PLAYERS IN PERIPHERAL VASCULAR DEVICES MARKET, 2023–2025 (USD MILLION) 336   FIGURE 31 GLOBAL SHARE ANALYSIS OF KEY PLAYERS IN PERIPHERAL VASCULAR DEVICES MARKET, 2025 337 FIGURE 32 US: PERIPHERAL VASCULAR DEVICES MARKET SHARE ANALYSIS, 2025 339 FIGURE 33 PERIPHERAL VASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 340 FIGURE 34 PERIPHERAL VASCULAR DEVICES MARKET: COMPANY FOOTPRINT, 2025 341 FIGURE 35 PERIPHERAL VASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 346 FIGURE 36 PERIPHERAL VASCULAR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 349 FIGURE 37 EV/EBITDA OF KEY VENDORS, 2024 349 FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 350 FIGURE 39 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT, 2025 356 FIGURE 40 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT, 2025 362 FIGURE 41 ABBOTT LABORATORIES: COMPANY SNAPSHOT, 2025 369 FIGURE 42 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT, 2025 375 FIGURE 43 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT, 2025 381 FIGURE 44 TERUMO CORPORATION: COMPANY SNAPSHOT, 2025 386 FIGURE 45 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT, 2025 391 FIGURE 46 B. BRAUN SE: COMPANY SNAPSHOT, 2025 395 FIGURE 47 MEDTRONIC: COMPANY SNAPSHOT, 2025 399 FIGURE 48 PENUMBRA, INC.: COMPANY SNAPSHOT, 2025 404 FIGURE 49 STRYKER CORPORATION: COMPANY SNAPSHOT, 2025 407 FIGURE 50 RESEARCH DESIGN 429 FIGURE 51 PRIMARY SOURCES 432 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS 433 FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS 434 FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 434 FIGURE 55 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 435 FIGURE 56 BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE ANALYSIS (2025) 436 FIGURE 57 PERIPHERAL VASCULAR DEVICES MARKET: SUPPLY-SIDE ANALYSIS 436 FIGURE 58 TOP-DOWN APPROACH 437 FIGURE 59 CAGR PROJECTIONS FROM ANALYSIS OF PERIPHERAL VASCULAR DEVICES MARKET DYNAMICS, 2026–2031 438 FIGURE 60 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF PERIPHERAL VASCULAR DEVICES MARKET, 2026–2031 439 FIGURE 61 DATA TRIANGULATION 441

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們